Top 5 Drug Type | Count |
---|---|
Hematopoietic stem cell therapy | 2 |
Gene therapy | 1 |
Stem cell therapy | 1 |
mRNA | 1 |
CAR-T | 1 |
Target |
Mechanism CD7 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Hemoglobins stimulants [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Gene transference |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date25 May 2023 |
Sponsor / Collaborator |
Start Date01 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BEAM-201 ( CD7 ) | T-cell acute lymphoblastic leukemia in relapse More | Phase 2 Clinical |
BEAM-101 ( Hemoglobins x KLKB1 x TTR ) | Anemia, Sickle Cell More | Phase 2 Clinical |
ESCAPE: Engineered Stem Cell Antibody Paired Evasion | Beta-Thalassemia More | Preclinical |
BEAM-102 ( Hemoglobins ) | Anemia, Sickle Cell More | Preclinical |
Cytosine base editing (Beam Therapeutics) | Hepatitis B More | Preclinical |